Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR16769] to Actin (HRP)
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Rat, Human
- Conjugation: HRP
Product nameAnti-Actin antibody [EPR16769] (HRP)
See all Actin primary antibodies
DescriptionRabbit monoclonal [EPR16769] to Actin (HRP)
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Chicken
Synthetic peptide within Human Actin aa 50-150. The exact sequence is proprietary.
Database link: P68133
- WB: HeLa, HEK293, Raw264.7, NIH3T3, PC12 whole cell lysates; Human Heart, Mouse Heart, Rat Heart tissue lysates. IHC-P: FFPE human kidney (normal) tissue sections.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Anti-Actin antibody [EPR16769] (ab179467)
- Anti-Actin antibody [EPR16769] (Alexa Fluor® 488) (ab206277)
- Anti-Actin antibody [EPR16769] (Alexa Fluor® 647) (ab206278)
- Anti-Actin antibody [EPR16769] (Alexa Fluor® 405) (ab207900)
- Anti-Actin antibody [EPR16769] (Alexa Fluor® 555) (ab208080)
- Anti-Actin antibody [EPR16769] (Alexa Fluor® 568) (ab208143)
- Anti-Actin antibody [EPR16769] - BSA and Azide free (ab219733)
Our Abpromise guarantee covers the use of ab207674 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|WB||1/5000. Detects a band of approximately 42 kDa (predicted molecular weight: 42 kDa).|
FunctionActins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.
Involvement in diseaseDefects in ACTA1 are the cause of nemaline myopathy type 3 (NEM3) [MIM:161800]. A form of nemaline myopathy. Nemaline myopathies are muscular disorders characterized by muscle weakness of varying severity and onset, and abnormal thread-or rod-like structures in muscle fibers on histologic examination. The phenotype at histological level is variable. Some patients present areas devoid of oxidative activity containg (cores) within myofibers. Core lesions are unstructured and poorly circumscribed.
Defects in ACTA1 are a cause of myopathy congenital with excess of thin myofilaments (MPCETM) [MIM:161800]. A congenital muscular disorder characterized at histological level by areas of sarcoplasm devoid of normal myofibrils and mitochondria, and replaced with dense masses of thin filaments. Central cores, rods, ragged red fibers, and necrosis are absent.
Defects in ACTA1 are a cause of congenital myopathy with fiber-type disproportion (CFTD) [MIM:255310]; also known as congenital fiber-type disproportion myopathy (CFTDM). CFTD is a genetically heterogeneous disorder in which there is relative hypotrophy of type 1 muscle fibers compared to type 2 fibers on skeletal muscle biopsy. However, these findings are not specific and can be found in many different myopathic and neuropathic conditions.
Sequence similaritiesBelongs to the actin family.
Cellular localizationCytoplasm > cytoskeleton.
- Information by UniProt
- a actin antibody
- a-actin antibody
- ACTA antibody
IHC image of Actin staining in a section of formalin-fixed paraffin-embedded normal human kidney tissue* performed on a Leica BONDTM. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab207674, 1/100 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
All lanes : Anti-Actin antibody [EPR16769] (HRP) (ab207674) at 1/5000 dilution
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 : HEK293 (Human) Whole Cell Lysate
Lane 3 : Human heart tissue lysate
Lane 4 : RAW 264.7 (Mouse leukaemic monocyte macrophage cell line) Whole Cell Lysate
Lane 5 : NIH 3T3 (Mouse) Whole Cell Lysate
Lane 6 : Mouse heart tissue lysate
Lane 7 : C6 (Rat glioma cell line) Whole Cell Lysate
Lane 8 : PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate
Lane 9 : Rat heart tissue lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 42 kDa
Observed band size: 42 kDa
Exposure time: 6 seconds
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab207674 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab207674 has not yet been referenced specifically in any publications.